Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets

doi:10.4330/wjc.v5.i4.75

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7510)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series.

Item

Count

PDF

378

HTML

5180

Figures (1-2)

282

Sum=5840

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

861

Download

810

Sum=1671

Apr 26, 2013 (publication date) through Nov 16, 2024

Times Cited of This Article

Times Cited (23)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Cardiol. Apr 26, 2013; 5(4): 75-86
Published online Apr 26, 2013. doi: 10.4330/wjc.v5.i4.75

Full Size Figure Download Figure

Figure 1 Schematic outline of sphingolipid metabolism. Names of the major intermediates and abbreviations of the enzymes involved are included. SM: Sphingomyelin; SphK: Sphingosine kinase; S1P: Sphingosine-1-phosphate.

Citation: Kawabori M, Kacimi R, Karliner JS, Yenari MA. Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets. World J Cardiol 2013; 5(4): 75-86
URL: https://www.wjgnet.com/1949-8462/full/v5/i4/75.htm
DOI: https://dx.doi.org/10.4330/wjc.v5.i4.75